The global peanut allergy treatment market was valued at USD 536.8 million in 2024 and is anticipated to grow to USD 1,461.5 million by 2033, achieving a CAGR of 11.43% from 2025 to 2033. This growth is being driven by the increasing prevalence of peanut allergies and advancements in therapeutic options. A notable trend is the shift from avoiding allergens to proactive treatments such as oral immunotherapy and biologics, which enhance patient quality of life. The market is evolving with new regulatory approvals and research and development efforts focused on safer and more effective solutions. This growth indicates a vibrant industry that addresses a significant health concern and presents vast opportunities for innovation.
Palforzia, the first oral immunotherapy for peanut allergies approved by the FDA, marks a crucial development in allergy treatment. Unlike traditional avoidance methods, Palforzia employs a controlled desensitization strategy to lessen the severity of allergic reactions. This therapy has shown improved clinical results and has been widely adopted, especially in North America, where it is expected that over 60% of eligible pediatric patients will transition to such immunotherapies by 2024. The market's expansion is also supported by heightened awareness of food allergies and advancements in diagnostic technologies, which stimulate the demand for novel and effective treatment options.
Key Market Trends & Insights
North America peanut allergy treatment industry dominated globally in 2024, capturing a substantial 37.31% of global revenue share. This leadership is primarily attributed to the United States, which accounted for approximately 85% of the region's market share. The U.S. market is bolstered by advanced healthcare infrastructure, high levels of allergy awareness, and robust regulatory support from agencies like the FDA.
By drug class, epinephrine held the largest share in the market with 46.63% in 2024, emphasizing its role as the primary emergency solution for anaphylaxis. Antihistamines are widely used for managing mild reactions, while immunotherapies, including Palforzia, show potential for long-term allergy management.
By route of administration, injectable treatment dominated the market in 2024, holding 61.72% share, primarily due to its rapid effectiveness in emergency situations. Epinephrine injections remain the gold standard for anaphylaxis management, ensuring immediate relief for severe allergic reactions.
By distribution channel, hospital pharmacies dominated in 2024 with a 55.46% share, as they handle initial immunotherapy doses under medical supervision and supply epinephrine for emergencies. Their critical role in specialized allergy care ensures their leadership, supported by integration with healthcare systems for high-risk patient management.
Market Size & Forecast
2024 Market Size: USD 536.8 Million
2033 Projected Market Size: USD 1.5 Billion
CAGR (2025-2033): 11.43%
North America: Largest Market in 2024
Asia Pacific: Fastest Growing Market
Order a free sample PDF of the peanut allergy treatment Market Intelligence Study, published by Grand View Research.
Key Companies & Market Share Insights
Aimmune Therapeutics leads the market with Palforzia, utilizing Nestlé’s resources for global expansion and R&D efforts. DBV Technologies is advancing its Viaskin Peanut product with a focus on non-invasive delivery methods to capture market share. Sanofi remains a leader in emergency treatments with epinephrine auto-injectors, emphasizing distribution capabilities. ALK-Abelló is exploring sublingual options, targeting niche growth. These companies are driving innovation and competition through strategic partnerships and investment in development pipelines.
Key Players
Aimmune Therapeutics (Nestlé Health Science)
DBV Technologies
Sanofi
ALK-Abelló
Prota Therapeutics
Camallergy
Aravax
Genentech
Conclusion
The peanut allergy treatment market is poised for significant growth driven by innovative therapies, increased patient awareness, and expanding access to healthcare solutions. The ongoing research and development efforts, coupled with strategic initiatives from key players, are expected to further enhance treatment options and improve patient outcomes in the coming years.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.